SOLIDaccuTest™ is an excellent tool for discovering variants associated with solid tumors using a comprehensive approach to next-generation sequencing (NGS). It reflects the latest research trends and is optimized for medical purposes by selecting essential genes of solid tumors including lung, colon, breast, skin brain, stomach and ovarian cancers, etc.

SOLIDaccuTest™ is an excellent tool to explorer variants associated with solid tumors using a comprehensive method of next-generation sequencing (NGS). It reflects the latest research trends and is optimized for the medical purpose by selecting essential genes of solid tumors including lung, colon, breast, skin brain, gastric, ovarian cancers, etc.

BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test

BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.

Product Information

Model: NextSeq 1000

Manufacturer: Illumina

Origin: Singapore/United States

Launching year: 01/2020

The PANA RealTyper™ HPV Screening Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC

DxFLEX is a new clinical flow cytometry platform derived from the successful CytoFLEX. The advanced sensitivity and intuitive software DxFLEX makes flow cytometry routine for both novice and expert flow cytometry technicians and promotes standardization. Functionality in the autoloader facilitates accurate results and sample tracking.

Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time

TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants

Developed with cancer genomics experts in collaboration, oligos ready-to-use, pre-engineered oligos allow researchers to sequence a wide range of genes and single nucleotide polymorphisms (SNPs) in advance. this is related to cancer predisposition